Compare Elanco Animal Health Incorporated Common Stock (ELAN) vs Honeywell Aerospace Inc. Common Stock (HONA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elanco Animal Health Incorporated Common Stock vs Honeywell Aerospace Inc. Common Stock — how do they compare? Elanco Animal Health Incorporated Common Stock trades at $22.55 (market cap $11.20B), while Honeywell Aerospace Inc. Common Stock trades at $155.9 (market cap $50.14B). The key difference: Honeywell Aerospace Inc. Common Stock is far larger — about 4.5× Elanco Animal Health Incorporated Common Stock's market cap, and Elanco Animal Health Incorporated Common Stock is trading nearer its 52-week high, Honeywell Aerospace Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Elanco Animal Health Incorporated Common Stock for 6 Days and Honeywell Aerospace Inc. Common Stock for 0 Days on average.
| ELAN | HONA | |
|---|---|---|
Market Cap | $11.20B | $50.14B |
Volume | 3,345,224 | 1,433,364 |
Sector | Health | Industrials |
52-Week High | $26.84 | $269.95 |
52-Week Low | $19.80 | $151.58 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $14.58B | $64.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELAN trades at $22.41, down 0.66% today, with a bearish technical signal from moving averages. The company reported a net loss of $232 million in 2025, though revenue grew to $4.72 billion. Recent earnings beats and a 71% analyst buy rating reflect optimism around new product launches like Zenrelia and deleveraging plans discussed at recent conferences.
The outlook hinges on execution of growth initiatives to achieve profitability. Upside exists if new products gain market share as projected, but risks include persistent losses, competitive pressures, and high debt. The consensus price target of $28.00 suggests 25% potential upside from current levels.
HONA trades at $158.18, up 0.58% today, with neutral technical indicators showing support at $156 and resistance at $160. The company reported Q2 2026 EPS of $1.87, missing expectations of $2.07, while revenue grew to $17.40B in 2025. Analyst consensus remains mixed with a $211.25 price target, but multiple class action lawsuits filed in October 2026 create significant legal overhang.
HONA faces near-term headwinds from earnings miss and legal challenges, though strong cash flow generation and analyst price targets suggest long-term potential. Investors should weigh the 42.9% buy rating against litigation risks and declining profit margins projected for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Elanco Animal Health Incorporated Common Stock
Elanco develops medicines, vaccines, and other health products for pets and livestock. Its products address prevention and treatment of animal diseases.
Read more on ELAN →About Honeywell Aerospace Inc. Common Stock
Honeywell Aerospace Inc. is an aerospace and defense technology company, spun off from Honeywell in June 2026, that designs and supplies avionics, propulsion components (including auxiliary power units and engines), and connectivity systems for commercial, defense, and space aircraft.
Read more on HONA →
